Qinlock

Active Ingredient(s): Ripretinib
FDA Approved: * May 15, 2020
Pharm Company: * DECIPHERA PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Qinlock Overview

Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.[2] It is taken by mouth.[2] Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.[2] The most common side effects include alopecia (hair loss), fatigue, nausea, abdominal pain, constipatio...

Read more Qinlock Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ripretinib

Recent Qinlock Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Ripretinib or a similar ingredient: (1 result)

• RIPRETINIB